By Malvika Gurung
Investing.com -- The pharmaceutical company Glenmark Pharmaceuticals (NS: GLEN ) reported its earnings for the March-ending quarter on Saturday, recording a fall in its profit figure in the period.
Its consolidated profit after tax declined 26% on a YoY basis to Rs 173 crore in Q4 FY22, compared to Rs 234 crore reported in the year-ago period.
Glenmark’s board of directors have recommended a dividend of Rs 2.5/share for FY22.
The company’s consolidated revenues climbed 6% YoY to Rs 3,019 crore in the quarter under review, and 12.4% YoY to Rs 12,305 crore in the full financial year 2021-22. In the year, its PAT marginally rose by 2.5% YoY to Rs 994 crore.
The firm successfully listed its subsidiary Glenmark Life Sciences (NS: GLEM ) in the Indian exchanges, out-licensed the deal for ISB 880 with Almirall and gained approval for the Ryaltris from the USFDA to establish the drug company as the leading innovation-driven pharma company in India, stated the company’s Chairman and MD Glenn Saldanha, as cited by PTI.
He added, “We delivered consistent performance throughout the year and achieved our key objectives, despite the challenging global macro environment.”
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.